נפח מכירות חזוי: Conduit Pharma (CDT)

Conduit Pharmaceuticals (CDT) generates revenue by licensing therapies for kidney and lung diseases, targeting the multi-billion dollar chronic pathology segment. On GURU.Markets, the company's projected sales are displayed within a sideways corridor, where 0.00 captures the magnitude of this parameter. Demand for such drugs remains stable regardless of GDP, while a strategy of acquiring existing assets minimizes scientific risks.

Assessing the margin of safety for Conduit Pharmaceuticals (CDT) requires an analysis of expected cash flows from asset realization. This indicator captures market expectations for future revenues, reflecting the capitalization of potential contracts. The trend in the company's planned sales allows investors to promptly determine the degree of business undervaluation. The upward trajectory confirms management's efficiency in selecting molecules for licensing. This verifies the sustainability of the labless model of reselling rights to pharmaceutical behemoths.